A Personalized Approach to the Management of Congestion in Acute Heart Failure [0.03%]
急性心力衰竭时 congestion管理的个体化方法
Gustavo R Moreira,Humberto Villacorta
Gustavo R Moreira
Heart failure (HF) is the common final pathway of several conditions and is characterized by hyperactivation of numerous neurohumoral pathways. Cardiorenal interaction plays an essential role in the progression of the disease, and the use o...
Michael Albosta,Jelani K Grant,Erin D Michos
Michael Albosta
The management of low-density lipoprotein cholesterol (LDL-C) levels is a central strategy for the prevention of atherosclerotic cardiovascular disease. Current United States (2018 American Heart Association/American College of Cardiology/M...
Sarcopenic Obesity as a Risk Factor for Cardiovascular Disease: An Underrecognized Clinical Entity [0.03%]
肌少型肥胖作为心血管疾病的风险因素：一个被忽视的临床实体
Aditya John Binu,Nitin Kapoor,Saptarshi Bhattacharya et al.
Aditya John Binu et al.
Sarcopenic obesity (SO) is a chronic condition and an emerging health challenge, in view of the growing elderly population and the obesity epidemic. Due to a lack of awareness among treating doctors and the non-specific nauture of the assoc...
Assessment and Management of Ischaemic Heart Disease in Non-Cardiac Surgery [0.03%]
非心脏手术中缺血性心脏病的评估与管理
Holly Morgan,Saad M Ezad,Haseeb Rahman et al.
Holly Morgan et al.
In the setting of non-cardiac surgery, cardiac complications contribute to over a third of perioperative deaths. With over 230 million major surgeries performed annually, and an increasing prevalence of cardiovascular risk factors and ischa...
Conduction System Pacing: Have We Finally Found the Holy Grail of Physiological Pacing? [0.03%]
传导系统起搏：我们是否终于找到了生理起搏的圣杯？
Myriam Kaddour,Haran Burri
Myriam Kaddour
The late fifties are considered a high point in the history of cardiac pacing, since this era is marked by the first pacemaker implantation, which has since evolved into life-saving therapy. Right ventricular apical and biventricular pacing...
Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations [0.03%]
钠-葡萄糖协同转运蛋白2抑制剂与心血管系统：目前的认识和未来的期望
Ioannis Boutsikos,Eleftherios Beltsios,Bastian Schmack et al.
Ioannis Boutsikos et al.
Diabetic cardiomyopathy is a well-recognized clinical entity and reflects a complex relationship between metabolic substrates and myocardial function. Sodium glucose co-transporter 2 (SGLT2) inhibitors are antidiabetic agents that are found...
Balloon Aortic Valvuloplasty in the Transcatheter Aortic Valve Implantation Era [0.03%]
经导管主动脉瓣植入术时代的球囊主动脉瓣成形术
Gustavo Arturo Samaja
Gustavo Arturo Samaja
As the population continues to grow, and life expectancy has increased, aortic stenosis (AS) has become the most common valvular disease requiring surgical treatment. The evolution of valve replacement therapies has progressed significantly...
Transcatheter Mitral Valve Replacement in Patients with Mitral Annular Calcification: A Review [0.03%]
经导管二尖瓣置换治疗二尖瓣环钙化患者：综述
Ankit Agrawal,Michael J Reardon,Sachin S Goel
Ankit Agrawal
Mitral annular calcification (MAC) is a progressive degenerative calcification of the mitral valve (MV) that is associated with mitral stenosis, regurgitation or both. Patients with MAC are poor candidates for MV surgery because of technica...
Bradycardia, Renal Failure, Atrioventricular Nodal Blockade, Shock and Hyperkalaemia Syndrome Involving Digoxin Toxicity: A Case Report [0.03%]
洋地黄中毒所致心动过缓、肾衰竭、房室传导阻滞、心源性休克及高血钾综合征1例报告
Meet Shah,Arthi Palani,Ashkan Hashemi et al.
Meet Shah et al.
Bradycardia, renal failure, atrioventricular nodal blockade, shock and hyperkalemia (BRASH) syndrome is named after the pentad of symptoms experienced by patients with this clinical entity, and is propagated via a synergistic mechanism. Her...
Mavacamten, an Alternative to Septal Reduction Therapy for Patients with Hypertrophic Cardiomyopathy [0.03%]
心室肥厚性心脏病患者的另一种治疗方法—— mavacamten替代降低心室壁治疗疗法
Milind Y Desai,Adel Hajj Ali
Milind Y Desai
Hypertrophic cardiomyopathy (HCM) is a common heridetary cardiac disorder characterized by a wide range of symptoms. The pharmacological treatment of HCM is currently limited to beta blockers, non-dihydropyridine calcium channel blockers an...